mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy
出版年份 2011 全文链接
标题
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 15, Issue 7, Pages 859-872
出版商
Informa Healthcare
发表日期
2011-04-09
DOI
10.1517/14728222.2011.575362
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer
- (2010) Vicky S. Sabine et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- mTOR regulation of autophagy
- (2010) Chang Hwa Jung et al. FEBS LETTERS
- Interactions between IGF-I, estrogen receptor- (ER ), and ER in regulating growth/apoptosis of MCF-7 human breast cancer cells
- (2010) R. A. Mendoza et al. JOURNAL OF ENDOCRINOLOGY
- ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis
- (2010) Craig I Campbell et al. Molecular Cancer
- Chronic Inhibition of the mTORC1/S6K1 Pathway Increases Insulin-Induced PI3K Activity but Inhibits Akt2 and Glucose Transport Stimulation in 3T3-L1 Adipocytes
- (2010) Alain Veilleux et al. MOLECULAR ENDOCRINOLOGY
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
- (2009) C. Sessa et al. ANNALS OF ONCOLOGY
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
- (2009) C. M. Hartford et al. CLINICAL CANCER RESEARCH
- 5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab
- (2009) F. Cardoso et al. EJC SUPPLEMENTS
- Growth Hormone Excess Promotes Breast Cancer Chemoresistance
- (2009) Maria Chiara Zatelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
- (2008) D. Generali et al. CLINICAL CANCER RESEARCH
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
- (2008) Jian-Hua Mao et al. SCIENCE
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
- (2007) Ahmad Awada et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started